샘플 요청 목록

 카트 문의
시장보고서
상품코드
1757888

세계의 자궁근종 치료 기기 시장

Uterine Fibroid Treatment Devices
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 276 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 자궁근종 치료 기기 시장은 2030년까지 81억 달러에 달할 전망

2024년에 53억 달러로 추정되는 세계의 자궁근종 치료 기기 시장은 2024-2030년에 CAGR 7.4%로 성장하며, 2030년에는 81억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 외과수술은 CAGR 8.7%를 기록하며, 분석 기간 종료시에는 53억 달러에 달할 것으로 예측됩니다. 절제 분야의 성장률은 분석 기간에 CAGR 5.1%로 추정됩니다.

미국 시장은 14억 달러로 추정, 중국은 CAGR 11.8%로 성장 예측

미국의 자궁근종 치료 기기 시장은 2024년에 14억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 17억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 11.8%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.6%와 7.2%로 예측됩니다. 유럽에서는 독일이 CAGR 4.9%로 성장할 것으로 예측됩니다.

세계의 "자궁근종 치료 기기" 시장 - 주요 동향과 촉진요인 정리

첨단 자궁근종 치료에 대한 수요가 증가하는 이유는 무엇인가?

자궁의 양성 종양인 자궁근종에 대한 전 세계 부담이 크게 증가하고 있으며, 50세까지 여성의 70-80%가 자궁근종을 앓고 있으며, 증상이 있는 경우 대량 출혈, 골반통, 불임 및 기타 합병증을 유발합니다. 이러한 발병률 증가는 특히 자궁 보존 수술을 원하는 가임기 여성의 경우, 효과적이고 덜 침습적인 치료법에 대한 수요에 직접적인 영향을 미치고 있습니다. 역사적으로 자궁적출술이 치료의 주류였으나, 환자들의 선호도는 자궁근종 적출술, 자궁동맥색전술(UAE), 복강경 수술 및 로봇 보조 수술과 같은 저침습적 수술과 같은 자궁 보존 수술로 점점 더 많이 이동하고 있습니다. 특히 생식력을 중시하는 문화권에서 자궁 적출술에 대한 낙인과 사회적 의미는 이러한 전환을 더욱 가속화시키고 있습니다. 또한 생활습관의 변화, 늦은 임신 기간, 비만이 위험을 증가시키는 요인으로 확인되어 조기 진단과 치료로 이어지고 있습니다. 헬스케어 산업이 여성 건강에 초점을 맞추고, 인식 개선 캠페인이 강화되면서 검진율과 진단율이 급증하고 있는 것도 자궁근종 치료 기기 시장을 더욱 촉진하고 있습니다.

기술과 혁신은 어떻게 치료법을 재정의하고 있는가?

혁신적인 혁신이 자궁근종 관리의 진화의 중심에 있으며, 의료기기 제조업체들은 임상 결과를 개선하고, 회복 기간을 단축하며, 수술 합병증을 줄이기 위해 최첨단 장비를 도입하고 있습니다. 고밀도집속초음파(HIFU), 고주파소작술(RFA), MRI 유도하 집속초음파수술(MRgFUS)과 같은 치료 기술은 비침습적 또는 저침습적 치료 접근법을 재정의하고 있습니다. 이 장비들은 주변 조직 손상 없이 자궁근종을 정확하게 조준할 수 있으며, 환자에게 부작용이 적고 빠른 완화와 외래 환자 수준의 편의성을 제공합니다. 또한 복강경 파워몰세레이터와 첨단 자궁경 기구는 특히 조직 파종에 대한 과거의 우려에 비추어 안전성을 향상시키기 위해 개선되고 있습니다. 로봇 수술 시스템은 고가이긴 하지만 복잡한 자궁근종 제거의 정확도를 높이기 위해 3차 의료 병원에서 채택되고 있습니다. 이러한 기술적 발전은 의사들의 신뢰를 높일 뿐만 아니라, 저층 병원과 외래 진료소까지 치료의 가능성을 넓혀 양질의 치료에 대한 접근성을 민주화하고 있습니다.

접근성을 확대하기 위해 의료 시스템과 의료 서비스 프로바이더는 무엇을 하고 있는가?

자궁근종 치료에 대한 접근성은 정책적 노력, 보험 적용 개혁, 진화하는 임상 가이드라인의 조합에 의해 형성되고 있습니다. 고소득 국가에서는 저침습적 외래 치료가 보험 적용을 받음으로써 비용이 낮아지고 치료 접근성이 높아졌습니다. 현재 많은 정부 및 민간 의료기관은 자궁근종 치료를 필수 여성 건강케어의 일부로 분류하여 진단, 의뢰 및 보조금 지원 프로세스를 개선하고 있습니다. 동시에 중저소득국가(LMICs)는 이동식 진단 장비에 대한 투자, 부인과 외과의사 연수 프로그램, 인식 개선을 위한 공중보건 캠페인 등을 통해 뒤처진 부분을 회복하고 있습니다. 다국적 NGO와 세계보건기구도 의료 선교에 자금을 지원하거나 지방 병원에 장비를 기증하는 등 역량 개발에 기여하고 있습니다. 또한 병원은 부인과, 영상의학과, 통증 관리를 결합한 다학제적 자궁근종 클리닉을 통합하여 환자가 근거에 기반한 적절한 치료를 받을 수 있도록 전인적 치료를 제공합니다. 외래 치료와 당일 퇴원 프로토콜로 전환하여 병원의 자원을 최적화하고 환자의 부담을 줄이고 있습니다.

자궁근종 치료기기 시장의 급성장 원동력은?

자궁근종 치료 기기 시장의 성장은 기술 발전, 임상 관행, 환자 선호도와 밀접한 관련이 있는 몇 가지 요인에 의해 주도되고 있습니다. 비침습적, 저침습적 기기의 보급으로 전통적인 개복 수술에서 치료 패턴이 크게 변화하고 있으며, 조기 회복과 가임력 보존을 원하는 환자들이 증가하고 있습니다. 경질초음파나 MRI와 같은 영상 진단 기술의 향상으로 진단 사례의 확대도 수술 건수를 증가시키고 있습니다. 자궁근종에 대한 인식이 높아짐에 따라 여성들은 조기 개입과 자궁적출술에 대한 대안을 적극적으로 찾고 있습니다. 또한 민간 및 공공 의료 서비스 프로바이더들은 시술의 효율성과 비용 대비 효과성이 뛰어나기 때문에 자궁근종 치료 장비에 대한 투자를 늘리고 있습니다. 특히 북미와 아시아태평양에서 외래 및 외래수술센터(ASC)의 존재감이 증가함에 따라 새로운 치료 장비의 상업적 잠재력이 확대되고 있습니다. 의료비 지출 증가, 출산 지연과 같은 인구 통계학적 변화, 비만과 호르몬 장애 발생률 증가는 수요를 더욱 촉진하고 있습니다. 이러한 요인들이 결합되어 향후 수년간 지속적인 시장 확대를 위한 견고하고 다각적인 기반을 형성하고 있습니다.

부문

기술(외과수술, 절제), 치료 모드(침습적, 저침습적, 비침습적)

조사 대상 기업의 예(총 42사)

  • AbbVie Inc.
  • Boston Scientific Corporation
  • CONMED Corporation
  • CooperSurgical Inc.
  • Ethicon, Inc.
  • Gynesonics
  • Hologic, Inc.
  • INSIGHTEC Ltd.
  • Karl Storz SE & Co. KG
  • Lumenis Be Ltd.
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Minerva Surgical, Inc.
  • Myovant Sciences GmbH
  • ObsEva SA
  • Olympus Corporation
  • Philips Healthcare
  • Profound Medical Corp.
  • Siemens Healthineers AG
  • Stryker Corporation

AI 통합

우리는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.07.04

Global Uterine Fibroid Treatment Devices Market to Reach US$8.1 Billion by 2030

The global market for Uterine Fibroid Treatment Devices estimated at US$5.3 Billion in the year 2024, is expected to reach US$8.1 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Surgical, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Ablation segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 11.8% CAGR

The Uterine Fibroid Treatment Devices market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 11.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global "Uterine Fibroid Treatment Devices" Market - Key Trends & Drivers Summarized

Why Is There a Rising Demand for Advanced Uterine Fibroid Treatments?

The global burden of uterine fibroids-benign tumors of the uterus-has grown substantially, affecting up to 70-80% of women by the age of 50, with symptomatic cases leading to heavy bleeding, pelvic pain, infertility, and other complications. This rising incidence is directly influencing the demand for effective, less invasive treatment modalities, particularly in reproductive-age women who seek uterine-sparing procedures. Historically, hysterectomy was the dominant treatment; however, patient preference is increasingly shifting toward uterus-preserving alternatives such as myomectomy, uterine artery embolization (UAE), and minimally invasive surgeries like laparoscopic and robotic-assisted interventions. The stigma and social implications of undergoing hysterectomy-especially in cultures where fertility is highly valued-are reinforcing this transition. In addition, lifestyle changes, late pregnancies, and obesity have been identified as risk-enhancing factors, leading to earlier diagnosis and treatment. The healthcare industry’s increased focus on women’s health and a surge in screening and diagnostic rates, due in part to better awareness campaigns, are further propelling the market for uterine fibroid treatment devices.

How Are Technology and Innovation Redefining Treatment Modalities?

Innovative breakthroughs are at the heart of the evolution in uterine fibroid management, with medical device manufacturers introducing cutting-edge equipment designed to improve clinical outcomes, shorten recovery periods, and reduce surgical complications. Technologies such as high-intensity focused ultrasound (HIFU), radiofrequency ablation (RFA), and MRI-guided focused ultrasound surgery (MRgFUS) are redefining non-invasive or minimally invasive treatment approaches. These devices enable precise targeting of fibroids without damaging surrounding tissues, offering patients rapid relief with fewer side effects and outpatient-level convenience. Additionally, laparoscopic power morcellators and advanced hysteroscopic tools are being refined to improve safety, especially in light of past concerns around tissue dissemination. Robotic surgical systems, though expensive, are increasingly employed in tertiary care hospitals to improve accuracy in complex fibroid removal. These technological advancements are not only increasing physician confidence but are also expanding treatment availability to lower-tier hospitals and outpatient clinics, democratizing access to quality care.

What Are Healthcare Systems and Providers Doing to Expand Access?

Access to fibroid treatment is being shaped by a combination of policy efforts, insurance coverage reforms, and evolving clinical guidelines. In high-income countries, broader insurance inclusion of less invasive and outpatient procedures has helped bring down costs and improve uptake. Many governments and private providers are now classifying uterine fibroid treatments as part of essential women’s healthcare, leading to better diagnosis, referral, and subsidization processes. At the same time, low- and middle-income countries (LMICs) are catching up, with investments in mobile diagnostic units, training programs for gynecologic surgeons, and public health campaigns aimed at raising awareness. Multinational NGOs and global health organizations are also contributing to capacity building by funding medical missions and donating devices to rural hospitals. Furthermore, hospitals are integrating multidisciplinary fibroid clinics combining gynecology, radiology, and pain management to offer holistic care, ensuring that patients receive tailored, evidence-based treatment options. The shift toward outpatient care and same-day discharge protocols is also optimizing hospital resources and reducing patient burden.

What’s Driving the Escalating Growth in the Uterine Fibroid Treatment Devices Market?

The growth in the uterine fibroid treatment devices market is driven by several factors closely linked to technology evolution, clinical practices, and patient preferences. The widespread availability of non-invasive and minimally invasive devices is dramatically shifting treatment patterns away from traditional open surgery, attracting a larger volume of patients seeking faster recovery and fertility preservation. The expanding pool of diagnosed cases-due to improved imaging techniques like transvaginal ultrasound and MRI-is also increasing procedural volumes. Patient behavior is playing a pivotal role; as awareness about fibroids rises, women are actively seeking early intervention and alternatives to hysterectomy. Additionally, private and public healthcare providers are increasingly investing in device-based fibroid treatments due to their procedural efficiency and favorable cost-benefit ratios. The increasing presence of outpatient and ambulatory surgery centers, particularly in North America and parts of Asia-Pacific, is expanding the commercial viability of newer treatment devices. Rising healthcare spending, demographic shifts such as delayed childbirth, and higher incidences of obesity and hormonal disorders are further fueling demand. Together, these factors form a robust and multifaceted foundation for sustained market expansion in the years ahead.

SCOPE OF STUDY:

The report analyzes the Uterine Fibroid Treatment Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Surgical, Ablation); Mode of Treatment (Invasive, Minimally Invasive, Non-Invasive)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • AbbVie Inc.
  • Boston Scientific Corporation
  • CONMED Corporation
  • CooperSurgical Inc.
  • Ethicon, Inc.
  • Gynesonics
  • Hologic, Inc.
  • INSIGHTEC Ltd.
  • Karl Storz SE & Co. KG
  • Lumenis Be Ltd.
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Minerva Surgical, Inc.
  • Myovant Sciences GmbH
  • ObsEva SA
  • Olympus Corporation
  • Philips Healthcare
  • Profound Medical Corp.
  • Siemens Healthineers AG
  • Stryker Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Uterine Fibroid Treatment Devices - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Uterine Fibroids Drives Demand for Minimally Invasive Treatment Devices
    • Patient Shift Toward Outpatient and Daycare Procedures Spurs Adoption of Non-Invasive Technologies
    • Innovation in MRI-Guided and Ultrasound-Based Devices Expands Addressable Patient Pool
    • Increasing Awareness Among Women Throws the Spotlight on Early Diagnosis and Treatment
    • Favorable Reimbursement Policies Strengthen Business Case for Advanced Device Adoption
    • Aging Population and Rising Obesity Rates Accelerate Demand for Fibroid Treatments
    • Integration of AI and Robotics in Surgical Devices Generates Clinical Efficiency Opportunities
    • Expansion of Women's Health Clinics in Emerging Markets Sustains Market Penetration
    • Preference for Uterus-Preserving Treatments Drives Demand for Focused Ultrasound Systems
    • Shorter Recovery Times and Lower Complication Risks Boost Adoption Across Age Groups
    • Lack of Access and Cultural Barriers in Rural Areas Pose Distribution and Awareness Challenges
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Uterine Fibroid Treatment Devices Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Uterine Fibroid Treatment Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Uterine Fibroid Treatment Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Surgical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Surgical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Surgical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Ablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Invasive by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Minimally Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Minimally Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Minimally Invasive by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Non-Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Non-Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Non-Invasive by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • JAPAN
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • CHINA
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • EUROPE
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Uterine Fibroid Treatment Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Uterine Fibroid Treatment Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • FRANCE
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • GERMANY
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Uterine Fibroid Treatment Devices by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Devices by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • INDIA
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Uterine Fibroid Treatment Devices by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Uterine Fibroid Treatment Devices by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Uterine Fibroid Treatment Devices by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Uterine Fibroid Treatment Devices by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • AFRICA
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제